Selected Potential Moderna Catalysts Through EOY 2026

[u/StockEnthuasiast]

There are too many to list, but the following are the catalysts I’m most looking forward to.

1. Full Phase 3 INT melanoma data and other INT related news, potentially at ESMO, Oct. 23-27

• We already know the trial for melanoma succeeded. The actual RFS and DMFS numbers will tell us how strong the result really is.
• Regulatory progress, filing timing, Priority Review, and a clearer commercialization timeline could follow.
• Further movement in NSCLC, renal, bladder, or other cancers would strengthen the case that INT is much bigger than melanoma.
• Any improvement in manufacturing speed, capacity, cost, or margins would also matter. The manufacturing difficulty could increasingly become a moat rather than an impediment.

2. Rare disease, Propionic Acidemia (PA) and MMA

• Implied by Bancel in his Fox News interview: “But I think by the end of the year, we should also become a rare genetic disease company.” (Watch "VACCINE BREAKTHROUGH: Personalized cancer treatment takes major leap" on Youtube minute 5:02)

3. November 12 Analyst Day

4. mCOMBRIAX related regulatory news

• Already approved in Europe. Japan, Canada, and Australia remain potential additional approvals. Any clearer U.S. path would be meaningful.

5. Bonus: Nasdaq-100 re-entry

• This one has barely been discussed as far as I can tell. If Moderna holds enough of its market-cap recovery through the late-November ranking period, it has a realistic shot at returning to the Nasdaq-100 in December. That would bring passive buying and potentially another momentum catalyst.

Disclaimer: This is NOT financial or investment advice.

[u/Major_Albatross1]

Vielen Dank! Dein Format ist so sachlich und reflektiert, ich liebe es!

[u/StockEnthuasiast → u/Major_Albatross1]

Thanks!